title: Suppression of metastases of small cell lung cancer cells in mice by a peptidic CXCR4 inhibitor TF14016.
abstract: CXCL12 is a chemokine essential for the organ-specific spread of a variety of cancers including small cell lung cancer (SCLC). Here, we examined the anti-metastatic efficacy of TF14016, a small peptidic inhibitor of CXCL12 receptor CXCR4, in SCLC. Treatment of mice with TF14016 significantly suppressed pulmonary metastases of CXCR4-expressing SCLC in size and number. Furthermore, histological examination revealed that the expression of vascular endothelial cell growth factor and the density of CD31-positive microvessels in metastatic foci were both significantly reduced in TF14016-treated mice. Collectively, CXCR4 could be an attractive target for anti-metastatic and anti-angiogenic therapy in SCLC.
authors.affiliation: Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka University Graduate School of Medicine, Osaka, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Otani
authors.forename: Takashi
authors.initials: T
authors.lastname: Kijima
authors.forename: Satoshi
authors.initials: S
authors.lastname: Kohmo
authors.forename: Shinya
authors.initials: S
authors.lastname: Oishi
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Minami
authors.forename: Izumi
authors.initials: I
authors.lastname: Nagatomo
authors.forename: Ryo
authors.initials: R
authors.lastname: Takahashi
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Hirata
authors.forename: Mayumi
authors.initials: M
authors.lastname: Suzuki
authors.forename: Koji
authors.initials: K
authors.lastname: Inoue
authors.forename: Yoshito
authors.initials: Y
authors.lastname: Takeda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Kida
authors.forename: Isao
authors.initials: I
authors.lastname: Tachibana
authors.forename: Nobutaka
authors.initials: N
authors.lastname: Fujii
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kumanogoh
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002448:Cell Adhesion / Q000187:drug effects; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000187:drug effects; D054377:Chemokine CXCL12 / Q000378:metabolism; D006801:Humans; D008175:Lung Neoplasms / Q000378:metabolism / Q000473:pathology*; D051379:Mice; D009362:Neoplasm Metastasis; D010455:Peptides / Q000494:pharmacology*; D019718:Receptors, CXCR4 / Q000037:antagonists & inhibitors*; D055752:Small Cell Lung Carcinoma / Q000378:metabolism / Q000473:pathology*; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis
chemical_list: C577039:4-fluorobenzoyl-Arg-Arg-Nal-Cys-Tyr-Cit-Lys-Lys-Pro-Tyr-Arg-Cit-Cys-Arg-NH2 (S-S bridged); D000970:Antineoplastic Agents; D054377:Chemokine CXCL12; D010455:Peptides; D019718:Receptors, CXCR4; D042461:Vascular Endothelial Growth Factor A